Karien Bloem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Karien Bloem has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Theo Rispens
Sanquin Research
8 shared publicationsAnnick de Vries
Sanquin Research
7 shared publications- Gerrit Jan Wolbink
Sanquin Research, Amsterdam, The Netherlands
4 shared publications Tiny Schaap
Sanquin Bloedvoorziening
4 shared publications- Theo Rispens
Department of Immunopathology Sanquin Research and Landsteiner Laboratory Amsterdam The Netherlands
3 shared publications - Annick de Vries
Sanquin Diagnostic Services Amsterdam The Netherlands
2 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70563
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.
- 30 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70563
Open AccessEvaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.
- Open Access
- 31 January 2024
- Published by Wiley
Early model-based precision-dosing at home to guide adalimumab therapy
1. Aims Underdosing of adalimumab can result in non-response and poor disease control. In this study we investigated the prediction of adalimumab levels with population pharmacokinetic model-based Bayesian forecasting early in therapy. This way underexposed non-responders can possibly be identified early to optimise disease control. 2. Methods A literature study was performed to identify adalimumab pharmacokinetic models. With data from a previous pharmacokinetic adalimumab study a model was evaluated retrospectively. In the prospective phase, a fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease patients with peak, trough and control adalimumab samples obtained by a volumetric absorptive microsampling technique and administration data from an electronic needle container. Steady state adalimumab levels were predicted from peak and trough levels collected after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalized root mean square error (RMSE). 3. Results An existing pharmacokinetic model was selected with external validation for the prospective phase. Thirty-six patients (22 rheumatologic and 14 IBD) were included in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was -2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum levels falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable levels of anti-adalimumab antibodies. 4. Conclusion This prospective study demonstrates that adalimumab levels at steady state can be predicted from early samples. This concept enables early precision dosing at home to guide therapy.
- 31 January 2024
- Published by Wiley
Open AccessEarly model-based precision-dosing at home to guide adalimumab therapy
1. Aims Underdosing of adalimumab can result in non-response and poor disease control. In this study we investigated the prediction of adalimumab levels with population pharmacokinetic model-based Bayesian forecasting early in therapy. This way underexposed non-responders can possibly be identified early to optimise disease control. 2. Methods A literature study was performed to identify adalimumab pharmacokinetic models. With data from a previous pharmacokinetic adalimumab study a model was evaluated retrospectively. In the prospective phase, a fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease patients with peak, trough and control adalimumab samples obtained by a volumetric absorptive microsampling technique and administration data from an electronic needle container. Steady state adalimumab levels were predicted from peak and trough levels collected after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalized root mean square error (RMSE). 3. Results An existing pharmacokinetic model was selected with external validation for the prospective phase. Thirty-six patients (22 rheumatologic and 14 IBD) were included in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was -2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum levels falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable levels of anti-adalimumab antibodies. 4. Conclusion This prospective study demonstrates that adalimumab levels at steady state can be predicted from early samples. This concept enables early precision dosing at home to guide therapy.
- 27 December 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (4) , 529-533
Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies
One reason for a lack of response to rituximab as well as infusion-related anaphylactic adverse events is the development of antidrug Abs to rituximab. Besides rituximab, a number of other therapeutic Abs targeting CD20 are nowadays available as alternatives. In this study, we investigated the potential cross-reactivity of (human) anti-rituximab Abs to three other anti-CD20 mAbs: ofatumumab, obinutuzumab, and ocrelizumab. In 25 cases of anti-rituximab Abs, cross-reactivity was examined using both direct binding assays and inhibition immunoassays. Although no cross-reactivity was observed to ofatumumab or obinutuzumab, 8 of 25 samples also showed reactivity toward ocrelizumab in at least one of the two assays. Furthermore, in three cases of anti-ocrelizumab Abs, cross-reactivity to rituximab was observed in an inhibition immunoassay, albeit not in a direct binding assay. Our results suggest that obinutuzumab or ofatumumab are safe anti-CD20 alternatives in case of the presence of anti-rituximab Abs. It is advisable to proceed cautiously if switching from rituximab to ocrelizumab (or vice versa) is considered in case these alternatives may not be available.
- 27 December 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (4) , 529-533
Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies
One reason for a lack of response to rituximab as well as infusion-related anaphylactic adverse events is the development of antidrug Abs to rituximab. Besides rituximab, a number of other therapeutic Abs targeting CD20 are nowadays available as alternatives. In this study, we investigated the potential cross-reactivity of (human) anti-rituximab Abs to three other anti-CD20 mAbs: ofatumumab, obinutuzumab, and ocrelizumab. In 25 cases of anti-rituximab Abs, cross-reactivity was examined using both direct binding assays and inhibition immunoassays. Although no cross-reactivity was observed to ofatumumab or obinutuzumab, 8 of 25 samples also showed reactivity toward ocrelizumab in at least one of the two assays. Furthermore, in three cases of anti-ocrelizumab Abs, cross-reactivity to rituximab was observed in an inhibition immunoassay, albeit not in a direct binding assay. Our results suggest that obinutuzumab or ofatumumab are safe anti-CD20 alternatives in case of the presence of anti-rituximab Abs. It is advisable to proceed cautiously if switching from rituximab to ocrelizumab (or vice versa) is considered in case these alternatives may not be available.
- Open Access
- 5 January 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (8) , 3162-3176
Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial
Aims: To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle.Methods: In this single‐centre double‐blind, placebo‐controlled, double‐dummy clinical trial in 24 healthy adults we compared 40 mg adalimumab (0.4 mL) administered i.d. using a hollow microneedle with a s.c. dose using a conventional needle. Primary parameters were pain, acceptability and local tolerability; secondary parameters safety, pharmacokinetics and immunogenicity. We explored usability of optical coherence tomography, clinical photography, thermal imaging, and laser speckle contrast imaging to evaluate skin reaction after i.d. injections. In vitro protein analysis was performed to assess compatibility of adalimumab with the hollow microneedle device.Results: While feasible and safe, injection pain of i.d. adalimumab was higher compared to s.c. adalimumab (35.4 vs. 7.9 on a 100‐point visual analogue scale). Initial absorption rate and relative bioavailability were higher after i.d. adalimumab (time to maximum plasma concentration = 95 h [47–120]; Frel = 129% [6.46%]) compared to s.c. adalimumab (time to maximum plasma concentration = 120 h [96–221]). Anti‐adalimumab antibodies were detected in 50% and 83% of the subjects after i.d. and s.c. adalimumab, respectively. We observed statistically significantly more erythema and skin perfusion after i.d. adalimumab, compared to s.c. adalimumab and placebo injections (P < .0001). Cytokine secretion after whole blood lipopolysaccharide challenge was comparable between administration routes.Conclusions: Intradermal injection of adalimumab using hollowing microneedles was perceived as more painful and less accepted than s.c. administration, but yields a higher relative bioavailability with similar safety and pharmacodynamic effects.
- 5 January 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (8) , 3162-3176
Open AccessComprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial
Aims: To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle.Methods: In this single‐centre double‐blind, placebo‐controlled, double‐dummy clinical trial in 24 healthy adults we compared 40 mg adalimumab (0.4 mL) administered i.d. using a hollow microneedle with a s.c. dose using a conventional needle. Primary parameters were pain, acceptability and local tolerability; secondary parameters safety, pharmacokinetics and immunogenicity. We explored usability of optical coherence tomography, clinical photography, thermal imaging, and laser speckle contrast imaging to evaluate skin reaction after i.d. injections. In vitro protein analysis was performed to assess compatibility of adalimumab with the hollow microneedle device.Results: While feasible and safe, injection pain of i.d. adalimumab was higher compared to s.c. adalimumab (35.4 vs. 7.9 on a 100‐point visual analogue scale). Initial absorption rate and relative bioavailability were higher after i.d. adalimumab (time to maximum plasma concentration = 95 h [47–120]; Frel = 129% [6.46%]) compared to s.c. adalimumab (time to maximum plasma concentration = 120 h [96–221]). Anti‐adalimumab antibodies were detected in 50% and 83% of the subjects after i.d. and s.c. adalimumab, respectively. We observed statistically significantly more erythema and skin perfusion after i.d. adalimumab, compared to s.c. adalimumab and placebo injections (P < .0001). Cytokine secretion after whole blood lipopolysaccharide challenge was comparable between administration routes.Conclusions: Intradermal injection of adalimumab using hollowing microneedles was perceived as more painful and less accepted than s.c. administration, but yields a higher relative bioavailability with similar safety and pharmacodynamic effects.
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (11) , 2129-2137
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study
- 1 November 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (11) , 2129-2137
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study
- Open Access
- 28 September 2020
- Published by Wiley
Favourable pharmacokinetics of intradermal adalimumab over subcutaneous administration: results of a randomized controlled trial
Aim To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle. Methods In this single-centre double-blind, placebo-controlled, double-dummy clinical trial in 24 healthy adults we compared 40 mg adalimumab (0.4 mL) administered i.d. using a hollow microneedle with a s.c. dose using a conventional needle. Primary parameters were pain, acceptability, and local tolerability; secondary parameters safety, pharmacokinetics and immunogenicity. We explored usability of optical coherence tomography (OCT), clinical photography, thermal imaging, and laser speckle contrast imaging (LSCI) to evaluate skin reaction after i.d. injections. In vitro protein analysis was performed to assess compatibility of adalimumab with the hollow microneedle device. Results While feasible and safe, injection pain of i.d. adalimumab was higher compared to s.c. adalimumab (35.4 vs. 7.9 on a 101-point VAS scale). Initial absorption rate and bioavailability were higher after i.d. adalimumab (Tmax=95h(47-120); F=129%(6.46%)) compared to s.c. adalimumab (Tmax=120h(96-221)). In 50% and 83% of the subjects anti-adalimumab antibodies were detected after i.d. and s.c. adalimumab, respectively. We observed statistically significantly more erythema and skin perfusion after i.d. adalimumab, compared to s.c. adalimumab and placebo injections (p<0.0001). Cytokine secretion after whole blood LPS challenge was comparable between administration routes. Conclusion Intradermal of adalimumab using hollowing microneedles was perceived as more painful, and less accepted than s.c. administration, however, yields a higher bioavailability with similar safety and pharmacodynamic effects.
- 28 September 2020
- Published by Wiley
Open AccessFavourable pharmacokinetics of intradermal adalimumab over subcutaneous administration: results of a randomized controlled trial
Aim To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle. Methods In this single-centre double-blind, placebo-controlled, double-dummy clinical trial in 24 healthy adults we compared 40 mg adalimumab (0.4 mL) administered i.d. using a hollow microneedle with a s.c. dose using a conventional needle. Primary parameters were pain, acceptability, and local tolerability; secondary parameters safety, pharmacokinetics and immunogenicity. We explored usability of optical coherence tomography (OCT), clinical photography, thermal imaging, and laser speckle contrast imaging (LSCI) to evaluate skin reaction after i.d. injections. In vitro protein analysis was performed to assess compatibility of adalimumab with the hollow microneedle device. Results While feasible and safe, injection pain of i.d. adalimumab was higher compared to s.c. adalimumab (35.4 vs. 7.9 on a 101-point VAS scale). Initial absorption rate and bioavailability were higher after i.d. adalimumab (Tmax=95h(47-120); F=129%(6.46%)) compared to s.c. adalimumab (Tmax=120h(96-221)). In 50% and 83% of the subjects anti-adalimumab antibodies were detected after i.d. and s.c. adalimumab, respectively. We observed statistically significantly more erythema and skin perfusion after i.d. adalimumab, compared to s.c. adalimumab and placebo injections (p<0.0001). Cytokine secretion after whole blood LPS challenge was comparable between administration routes. Conclusion Intradermal of adalimumab using hollowing microneedles was perceived as more painful, and less accepted than s.c. administration, however, yields a higher bioavailability with similar safety and pharmacodynamic effects.
- Open Access
- 30 March 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (7) , 1544-1551
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
Aims: Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay between blood samples taken at trough and availability of results, dose adjustments can only be carried out at the next infusion, typically 8 weeks later. Dried blood samples (DBS) performed at home to measure IFX concentrations can reduce the time to adapt dose/dosing interval. Here, we aimed to validate the clinical application of DBS for IFX in IBD patients and to evaluate the feasibility of home sampling.Methods: DBS results from 40 IBD patients on IFX treatment were compared to serum sample results at trough, peak, and 3–5 weeks after IFX infusion. Subsequently, patients performed DBS home sampling one week before the next IFX infusion. These were compared to serum concentrations as predicted by Bayesian analysis.Results: IFX concentrations from finger prick and venous puncture correlate well. DBS IFX concentrations showed high correlation with serum IFX concentrations (Spearman correlation: ≥0.965), without bias. Passing‐Bablok regression for IFX concentrations in DBS from home sampling also showed no bias (intercept: 1.02 mg L−1 (95% CI −1.77–2.04 mg L−1), slope: 0.82 (95% CI 0.63–1.40)), with reasonable correlation (Spearman correlation: 0.671).Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home‐sampled DBS. DBS is a reliable method to measure IFX and can be used to predict IFX trough concentrations.
- 30 March 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (7) , 1544-1551
Open AccessDried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
Aims: Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay between blood samples taken at trough and availability of results, dose adjustments can only be carried out at the next infusion, typically 8 weeks later. Dried blood samples (DBS) performed at home to measure IFX concentrations can reduce the time to adapt dose/dosing interval. Here, we aimed to validate the clinical application of DBS for IFX in IBD patients and to evaluate the feasibility of home sampling.Methods: DBS results from 40 IBD patients on IFX treatment were compared to serum sample results at trough, peak, and 3–5 weeks after IFX infusion. Subsequently, patients performed DBS home sampling one week before the next IFX infusion. These were compared to serum concentrations as predicted by Bayesian analysis.Results: IFX concentrations from finger prick and venous puncture correlate well. DBS IFX concentrations showed high correlation with serum IFX concentrations (Spearman correlation: ≥0.965), without bias. Passing‐Bablok regression for IFX concentrations in DBS from home sampling also showed no bias (intercept: 1.02 mg L−1 (95% CI −1.77–2.04 mg L−1), slope: 0.82 (95% CI 0.63–1.40)), with reasonable correlation (Spearman correlation: 0.671).Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home‐sampled DBS. DBS is a reliable method to measure IFX and can be used to predict IFX trough concentrations.
- 4 June 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (11) , 815-823
Capillary Blood Microsampling to Determine Serum Biopharmaceutical Concentration: Mitra ® Microsampler vs Dried Blood Spot
Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional venepuncture sampling. We investigated an alternative to dried blood spot collection on filter paper: sampling capillary blood using the Mitra® microsampler. Materials and Methods: Therapeutic monoclonal antibodies were spiked in whole blood, sampled using filter paper and Mitra microsampler and concentrations measured using specific ELISAs. Results: Good recoveries of adalimumab, infliximab, ustekinumab, vedolizumab, tocilizumab, natalizumab and rituximab were found up to 1 month of storage at room temperature, averaging 95.2% for the Mitra microsampler and 92.9% for Whatman® paper. Both hemoglobin and potassium yield satisfactory estimates for the volume of the cellular fraction of blood samples in combination with the Mitra microsampler. Conclusion: We established practical protocols for the estimation of serum/plasma c...
- 4 June 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (11) , 815-823
Capillary Blood Microsampling to Determine Serum Biopharmaceutical Concentration: Mitra ® Microsampler vs Dried Blood Spot
Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional venepuncture sampling. We investigated an alternative to dried blood spot collection on filter paper: sampling capillary blood using the Mitra® microsampler. Materials and Methods: Therapeutic monoclonal antibodies were spiked in whole blood, sampled using filter paper and Mitra microsampler and concentrations measured using specific ELISAs. Results: Good recoveries of adalimumab, infliximab, ustekinumab, vedolizumab, tocilizumab, natalizumab and rituximab were found up to 1 month of storage at room temperature, averaging 95.2% for the Mitra microsampler and 92.9% for Whatman® paper. Both hemoglobin and potassium yield satisfactory estimates for the volume of the cellular fraction of blood samples in combination with the Mitra microsampler. Conclusion: We established practical protocols for the estimation of serum/plasma c...
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients
- 22 August 2017
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (11) , 2474-2484
Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases
Aims: Development of a self‐sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti‐adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases.Methods: In this cross‐sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach.Results: Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2).Conclusions: We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab.
- 22 August 2017
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (11) , 2474-2484
Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases
Aims: Development of a self‐sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti‐adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases.Methods: In this cross‐sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach.Results: Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2).Conclusions: We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab.